CDH5 and neoplasm: Treating the system with a clinically-approved integrin β3-targeting antiplatelet drug impaired platelet aggregation and activation, decreased mesenchymal marker expression in tumor cells, downregulated phosphorylation of VE-cadherin in ECs, lowered the permeability of the MVNs, all contributing to a reduction in tumor cell extravasation rates.